InterMune sells Actimmune to Vidara for $55mm
Executive Summary
Fibrotic disease drug developer InterMune Inc. has sold its interferon gamma-1b therapy Actimmune to Irish spec pharma Vidara Therapeutics Research Ltd. for $55mm in cash, plus a two-year royalty stream.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
- Product Purchase
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice